@LillyDiabetesIn Profile picture

Lilly Diabetes International

@LillyDiabetesIn

Channel for the Professional Diabetes Community. Follow us for congress news, interviews & useful Diabetes info. X guidelines. https://t.co/G6ydkRJvCI

Joined April 2022
Similar User
EndoPrincesa photo

@EndoPrincesa

Ana Cebrián photo

@anicebrian

Christian Alvarado M.D. Obesity Medicine. photo

@DrAlvaradoFl

Reyes Ravé García photo

@reyes_rave

Dr Akhlaque Uddin photo

@UddinAkhlaque

Isabel Izquierdo photo

@IsabelI50037084

isabeleiva photo

@isabeleiva2

Suzanne Rowcliffe photo

@suzirowcliffe

Grzegorz Krzak photo

@grzkrzak

carolina lopez photo

@krolopezc

Tonet Serés Noriega photo

@tonetseres

Lilly proudly stands with the global diabetes community this #WorldDiabetesDay. We’re driven by our purpose: uniting caring and discovery to create medicines that make life better. Follow us for continuous updates.

Tweet Image 1

Therapeutic inertia has been associated with a reduced quality of life for patients with #Type2Diabetes, along with increased risks of morbidity and mortality.¹ What strategies for improving #Diabetes care are you exploring in clinical practice?

Tweet Image 1

We are thrilled to support the first-ever IDF-Europe Advocate Prize, recognizing outstanding advocates who made a real impact on the lives of people living with #Diabetes. Join us in honoring their contributions during the #WorldDiabetesDay celebrations!

Tweet Image 1

Join us on #WorldDiabetesDay! It is an important opportunity to reflect on how diabetes impacts millions of lives. At Lilly, we have been committed to improving #DiabetesCare for more than a century. Follow us for more!

Tweet Image 1

Over half a billion people around the globe live with diabetes. The prevalence of diabetes has grown in the last decade, but so has our commitment to helping people have a chance at better health. Our work to find new solutions for them is far from over. #WorldDiabetesDay


As #WorldDiabetesDay approaches, it’s important to prioritize the well-being of those living with diabetes. At Lilly, we are dedicated to innovative research and collaboration to make a meaningful impact in #DiabetesCare. Follow us for more insights on diabetes.

Tweet Image 1

One day, we hope people living with diabetes will be free from the burden of their disease. But until we can achieve that goal, we remain committed to paving the way for a better diabetes care around the world. Together, we can make a difference. #WorldDiabetesDay


Exciting News! On #WorldDiabetesDay the International Diabetes Federation Europe, supported by Lilly, will be hosting two events at the EU Parliament to focus on advancing the conversation around #DiabetesCare and prevention.

Tweet Image 1

#WorldDiabetesDay is around the corner! Let’s use the opportunity to raise awareness for #DiabetesCare. Together, a healthier future is within reach. Follow us for more updates and insights!

Tweet Image 1

When is #Type2Diabetes care stepped up to reach target HbA1c levels? The DISCOVER study showed that intensification of glycemic management is typically delayed by 4—7 years with a median HbA1c >8%/64 mmol/mol. How can early and tight glycemic control be achieved?


Do you tailor HbA1c targets for patients with #Type2Diabetes? The ADA/EASD consensus recommends personalizing glycemic targets based on each individual's preferences and characteristics.

Tweet Image 1

What is the impact of early and tight glycemic control in #T2D? The Diabetes & Aging study found that tight control in the first year after diagnosis reduces the 10-year risk of macro- and microvascular complications. Early management is key!


What is therapeutic inertia in #Type2Diabetes? The ADA/EASD consensus highlights that therapeutic inertia happens when goals or targets are not met, and diabetes management strategies are not adapted.¹ How can the burden of therapeutic inertia in #Diabetes be reduced?

Tweet Image 1

Could some patients with #Type2Diabetes benefit from tighter HbA1c targets? Aiming for a lower HbA1c level than <7% may have value when it can be achieved without a large risk of hypoglycemia.

Tweet Image 1

What are the benefits of early and tight glycemic control (HbA1c <7%) in #T2D observed in UKPDS? | For HCPs


Early detection of #Type2Diabetes and intensive glucose control from diagnosis is essential to maximize reduction of the long-term risk of glycemic complications. But what drives the impacts of early hyperglycemia?

Tweet Image 1

UKPDS showed a legacy effect with intensive management of newly-diagnosed #Type2Diabetes vs diet and lifestyle modification. Intensive management from diagnosis reduced the risk of diabetes-related complications, but how long were these effects maintained?¹⁻³,*


Based on UKPDS, early and tight glycemic control had a greater impact on clinical outcomes than delayed glycemic control in patients with type 2 diabetes.

Tweet Image 1

As #EASD2024 comes to a close, we want to thank everyone for the inspiring discussions and insights shared. Let’s keep the conversation alive — follow us for more discussions.

Tweet Image 1

What an amazing experience! 👋 #EASD2024 has concluded, and we’ve had the chance to explore the latest insights in #Diabetes and #WeightManagement! We’re already excited and gearing up for next year’s event.


This account does not follow anyone
Loading...

Something went wrong.


Something went wrong.